Furthermore, since a low MITF/AXL ratio was recognised as a predictor of early resistance [36], microRNA (miRNA) regulation of MITF expression was also explored as a novel therapeutic target to reverse the resistant phenotype [62,63,64] among many other miRNA pathways dysregulated in melanoma [65]. The gene discussed is AXL; the disease is melanoma.